A 50-year-old female underwent chemotherapy with docetaxel as third-line therapy for postoperative recurrence of lung adenocarcinoma for about 10 years. She had a skin rash at the first dose of docetaxel but was able to continue the treatment with antihistamine premedication. In August 2021, she received the coronavirus disease 2019 (COVID-19) vaccine. After that, she was able to be administered the 129th course of docetaxel without any problems in August. However, she developed skin rash and dyspnea after the 130th and 131st courses of docetaxel, and the treatment was discontinued. Hypersensitivity reactions to taxanes usually occur in the early stages of treatment, but this patient developed a hypersensitivity reaction after long-term treatment, which was atypical. Docetaxel solvents such as polyethylene glycol and polysorbate 80 appeared to be responsible for the hypersensitivity reaction. We considered the influence of the COVID-19 vaccine administered about 2 months before the docetaxel treatment, and we report this case because it seemed to be a valuable one.